Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia 3 Hematologic Neoplasms 3 Multiple Myeloma 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Unresectable Pancreatic Carcinoma 1 Triple Negative Breast Neoplasms 1 Sarcoma, Kaposi 1 Respiratory Tract Infections 1 Respiratory Distress Syndrome 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pneumonia 1 Pancreatic Neoplasms 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multi-centric Castleman's Disease 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immune-related Adverse Events 1

Interventions

Rituximab 117 Cyclophosphamide 104 fludarabine phosphate 52 Peripheral Blood Stem Cell Transplantation 52 Cytarabine 47 Etoposide 44 Mycophenolic Acid 41 Filgrastim 40 Whole-Body Irradiation 37 Tacrolimus 36 Melphalan 35 Bortezomib 34 Methotrexate 33 Cyclosporine 33 Busulfan 31 Radiotherapy 30 Vincristine 28 Doxorubicin 27 Dexamethasone 27 Carmustine 25 Antilymphocyte Serum 25 Lenalidomide 23 Bendamustine Hydrochloride 23 ibrutinib 22 Granulocyte Colony-Stimulating Factor 20 obinutuzumab 18 fludarabine 18 acalabrutinib 18 Prednisone 18 venetoclax 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphoma, Mantle-Cell × tocilizumab × Clear all

NCT05833763 2024-01-08

GOlDiLOX

Australasian Leukaemia and Lymphoma Group

Phase 2 Recruiting

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡